These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 6443688)

  • 1. Antidysentery immunoprophylaxis in the light of current data about the pathogenicity of Shigella and the antidysentery immunity.
    Meitert T
    Arch Roum Pathol Exp Microbiol; 1984; 43(3-4):195-230. PubMed ID: 6443688
    [No Abstract]   [Full Text] [Related]  

  • 2. Development and administration of live Shigella vaccines.
    Pencu E
    Arch Roum Pathol Exp Microbiol; 1984; 43(3-4):231-50. PubMed ID: 6443689
    [No Abstract]   [Full Text] [Related]  

  • 3. Vaccine strain Sh. flexneri T32-Istrati. Studies in animals and in volunteers. Antidysentery immunoprophylaxis and immunotherapy by live vaccine Vadizen (Sh. flexneri T32-Istrati).
    Meitert T; Pencu E; Ciudin L; Tonciu M
    Arch Roum Pathol Exp Microbiol; 1984; 43(3-4):251-78. PubMed ID: 6400299
    [No Abstract]   [Full Text] [Related]  

  • 4. An update on Shigella vaccines.
    Ashkenazi S; Cohen D
    Isr J Med Sci; 1994; 30(5-6):495-7. PubMed ID: 8034510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Safety, reactivity and effectiveness testing of live shigella flexneri vaccines in laboratory animals and children (author's transl)].
    Sergeev VV; Elkina SI; Solodnikov YP; Shuster BY; Sergeeva GS; Bulk VF; Bobkin SV
    Acta Microbiol Acad Sci Hung; 1974; 21(1-2):121-8. PubMed ID: 4216247
    [No Abstract]   [Full Text] [Related]  

  • 6. [Experimental model of keratoconjunctival infections in the study of immunity against Shigella].
    Cefalù M; Puglisi C
    G Mal Infett Parassit; 1972 Apr; 24(4):281-9. PubMed ID: 5050309
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunogenicity of living attenuated shigellae.
    Serény B; Tenner C; Rácz P
    Acta Microbiol Acad Sci Hung; 1971; 18(4):239-45. PubMed ID: 4950775
    [No Abstract]   [Full Text] [Related]  

  • 8. [Stimulation of antidysentery immunity with acetoxan].
    Gorbunova ES
    Antibiotiki; 1966 Apr; 11(4):354-8. PubMed ID: 4861976
    [No Abstract]   [Full Text] [Related]  

  • 9. Live dysentery vaccine "Vadizen" (T32-Istrati) immunogenicity against Shigella-like challenge in animals.
    Ciudin L; Meitert T; Pencu E; Gheorghe G; Tonciu M; Mihai I; Manase R
    Arch Roum Pathol Exp Microbiol; 1986; 45(3-4):247-56. PubMed ID: 3300598
    [No Abstract]   [Full Text] [Related]  

  • 10. Live-attenuated Shigella vaccines.
    Venkatesan MM; Ranallo RT
    Expert Rev Vaccines; 2006 Oct; 5(5):669-86. PubMed ID: 17181440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies for development of potential candidate Shigella vaccines.
    Lindberg AA; Pál T
    Vaccine; 1993; 11(2):168-79. PubMed ID: 8438615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain.
    Ranallo RT; Thakkar S; Chen Q; Venkatesan MM
    Vaccine; 2007 Mar; 25(12):2269-78. PubMed ID: 17229494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenic value of live, inactivated and cell-free dysentery vaccines.
    Meitert T; Sulea IT; Gogulescu L; Baron E; Tempea C; Istrati G
    Acta Microbiol Acad Sci Hung; 1974; 21(1-2):103-7. PubMed ID: 4613127
    [No Abstract]   [Full Text] [Related]  

  • 14. [Comparative immunomorphological study of the immunogenic activity of dysentery vaccines produced by different methods].
    Belaia IuA; Rukhamina ML; Nguyen ZH
    Zh Mikrobiol Epidemiol Immunobiol; 1983 Jul; (7):64-70. PubMed ID: 6353818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuated Salmonella typhi and Shigella as live oral vaccines and as live vectors.
    Levine MM; Galen J; Barry E; Noriega F; Tacket C; Sztein M; Chatfield S; Dougan G; Losonsky G; Kotloff K
    Behring Inst Mitt; 1997 Feb; (98):120-3. PubMed ID: 9382732
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunization of Mice with a Live Transconjugant Shigella Hybrid Strain Induced Th1 and Th17 Cell-Mediated Immune Responses and Confirmed Passive Protection Against Heterologous Shigellae.
    Nag D; Koley H; Sinha R; Mukherjee P; Sarkar C; Withey JH; Gachhui R
    Scand J Immunol; 2016 Feb; 83(2):92-101. PubMed ID: 26478541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis, genetics of virulence, and immunity in Shigellosis.
    Formal SB; Kapfer C; Hale TL
    Kansenshogaku Zasshi; 1988 Mar; 62 Suppl():329-42. PubMed ID: 3138359
    [No Abstract]   [Full Text] [Related]  

  • 18. Cross-protection provided by live Shigella mutants lacking major antigens.
    Szijártó V; Hunyadi-Gulyás E; Emődy L; Pál T; Nagy G
    Int J Med Microbiol; 2013 May; 303(4):167-75. PubMed ID: 23567193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An attenuated Shigella mutant lacking the RNA-binding protein Hfq provides cross-protection against Shigella strains of broad serotype.
    Mitobe J; Sinha R; Mitra S; Nag D; Saito N; Shimuta K; Koizumi N; Koley H
    PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005728. PubMed ID: 28727722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunity to experimental mouse shigellosis.
    Rauss K; Kétyi I
    Arch Immunol Ther Exp (Warsz); 1968; 16(3):491-6. PubMed ID: 5666686
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.